trending Market Intelligence /marketintelligence/en/news-insights/trending/sXG5JXRfHVgJOs4jg7TsTA2 content esgSubNav
In This List

UroGen's rare bladder cancer drug accepted for US FDA priority review

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook


UroGen's rare bladder cancer drug accepted for US FDA priority review

UroGen Pharma Ltd.'s experimental medicine to treat a rare type of bladder cancer has been accepted for priority review by the U.S. Food and Drug Administration.

The medicine, UGN-101, also known as mitomycin gel, is intended for low-grade upper tract urothelial cancer. The drug candidate will receive a decision on approval from the FDA by April 18, 2020, New York-based UroGen said in its Dec. 19 press release.

During clinical trials, UGN-101 was able to reduce or eliminate patients' cancer for about 13 months.

If approved, UGN-101, which has also received orphan-drug, fast-track and breakthrough-therapy designations, will be the first nonsurgical treatment for low-grade upper tract urothelial cancer, according to UroGen.